Lambert Nicole
Known title: DirectorCIK: 0001770252
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
Myriad Genetics Faces Risk Concerns Highlighted in Recent Analysis. An analysis on Yahoo points out three major risks for Myriad Genetics, raising questions about the company's future prospects. The stock is trading near its 14‑touch support level of $4.55 and sits above the 52‑week low of $2.74. Analysts average a target of $3.37, with a range from $2.00 to $5.00, suggesting a cautious view. The broader diagnostics market is also seeing growth, which may influence Myriad’s competitive environment.
Transaction History
| RCUS | ▲ Buy | Grant | 5,700 | $0 | 6/11/2026 | View on chart |
| RCUS | ▲ Buy | Grant | 13,300 | $0 | 6/10/2025 | View on chart |
| RCUS | ▲ Buy | Grant | 8,400 | $0 | 6/6/2024 | View on chart |
| MYGN | ▼ Sell | Tax Withholding | 4,864 | $73K | 10/9/2023 | View on chart |
| MYGN | ▼ Sell | Tax Withholding | 7,247 | $109K | 10/9/2023 | View on chart |
| MYGN | ▼ Sell | Tax Withholding | 4,402 | $70K | 9/26/2023 | View on chart |
| RCUS | ▲ Buy | Grant | 6,800 | $0 | 6/15/2023 | View on chart |
| MYGN | ▼ Sell | Open Market | 6,433 | $151K | 3/27/2023 | View on chart |
| MYGN | ▼ Sell | Tax Withholding | 2,143 | $51K | 3/24/2023 | View on chart |
| MYGN | ▼ Sell | Tax Withholding | 3,124 | $74K | 3/24/2023 | View on chart |
| MYGN | ▼ Sell | Tax Withholding | 2,419 | $55K | 3/22/2023 | View on chart |
| MYGN | ▲ Buy | Grant | 39,405 | $0 | 3/15/2023 | View on chart |
| MYGN | ▼ Sell | Open Market | 13,184 | $300K | 3/2/2023 | View on chart |
| MYGN | ▼ Sell | Tax Withholding | 853 | $12K | 1/1/2023 | View on chart |
| MYGN | ▼ Sell | Tax Withholding | 4,867 | $95K | 10/9/2022 | View on chart |
| MYGN | ▼ Sell | Tax Withholding | 7,251 | $142K | 10/9/2022 | View on chart |
| MYGN | ▼ Sell | Tax Withholding | 2,950 | $54K | 9/26/2022 | View on chart |
| MYGN | ▼ Sell | Tax Withholding | 642 | $12K | 9/25/2022 | View on chart |
| MYGN | ▼ Sell | Tax Withholding | 1,132 | $28K | 8/25/2022 | View on chart |
| RCUS | ▲ Buy | Grant | 4,100 | $0 | 6/14/2022 | View on chart |
| MYGN | ▼ Sell | Tax Withholding | 2,169 | $55K | 3/24/2022 | View on chart |
| MYGN | ▼ Sell | Tax Withholding | 3,178 | $80K | 3/24/2022 | View on chart |
| MYGN | ▲ Buy | Grant | 33,665 | $0 | 3/22/2022 | View on chart |
| MYGN | ▲ Buy | Grant | 43,295 | $0 | 2/16/2022 | View on chart |
| MYGN | ▲ Buy | Grant | 10,000 | $0 | 12/8/2021 | View on chart |
| MYGN | ▼ Sell | Tax Withholding | 5,013 | $155K | 10/9/2021 | View on chart |
| MYGN | ▼ Sell | Tax Withholding | 7,470 | $231K | 10/9/2021 | View on chart |
| MYGN | ▼ Sell | Open Market | 1,420 | $45K | 10/1/2021 | View on chart |
| MYGN | ▼ Sell | Open Market | 10,112 | $335K | 9/27/2021 | View on chart |
| MYGN | ▼ Sell | Tax Withholding | 3,426 | $114K | 9/26/2021 | View on chart |
| MYGN | ▼ Sell | Tax Withholding | 1,311 | $44K | 9/25/2021 | View on chart |
| MYGN | ▲ Buy | Grant | 65,870 | $0 | 9/21/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Arcus Biosciences gets JP Morgan coverage, adds grant program
JP Morgan started coverage of Arcus Biosciences with an Overweight rating and set a price target of $41. The firm’s initiation follows recent announcements that the company will provide new employment inducement grants to its staff. The coverage adds to an average analyst target of $40 and comes as the stock trades near the lower end of its 52‑week range. These developments may influence market perception of the company.
Arcus Biosciences gets JP Morgan coverage, adds grant program. JP Morgan started coverage of Arcus Biosciences with an Overweight rating and set a price target of $41. The firm’s initiation follows recent announcements that the company will provide new employment inducement grants to its staff. The coverage adds to an average analyst target of $40 and comes as the stock trades near the lower end of its 52‑week range. These developments may influence market perception of the company.